<DOC>
	<DOCNO>NCT00491764</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability oral administration four dose regimen posaconazole relative placebo terbinafine , treatment toenail onychomycosis .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Four Posaconazole Regimens With Placebo Terbinafine Treatment Toenail Onychomycosis ( Study P05082AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>The subject must meet ALL criterion list entry : Subject must 18 75 year age inclusive , either sex , race ; Subject must distal subungual infection affect approximately 25 % 75 % least one great toenail , clinically mycologically diagnose ; Subject must least 2 mm proximal end target toenail free infection ; Subject must target toenail assess capable grow approximately 1 mm/month , ( eg , subject need report cut toenail least per month ) ; Subject must liver function test within 1.5 x upper limit normal ( bilirubin transaminase ) ; Subject must normal serum creatinine level ; Subject must able take study medication orally ; Subject must history current narcotic alcohol addiction ; Subject must willing give write informed consent able adhere dose , procedure , visit schedule ; Woman childbearing potential currently sexually active must agree use medically accept method contraception receive protocolspecified medication 30 day stop medication . Methods include condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicide , medically prescribe intrauterine device , oral systemic hormonal contraceptive ( plus additional reliable barrier method ) , surgical sterilization ( eg , hysterectomy tubal ligation ) . Woman childbearing potential currently sexually active must agree use medically accept method contraception become sexually active participate study . Woman childbearing potential must negative serum pregnancy test within 72 hour prior start study drug . The subject exclude entry ANY criterion list meet : Subject one follow condition target toenail : proximal subungual onychomycosis , white superficial onychomycosis , dermatophytoma `` yellow spike/streak '' , exclusively lateral disease , inability become normal opinion investigator . Subject psoriasis , severe moccasintype tinea pedis require treatment , symptomatic interdigital tinea pedis , lichen planus , abnormality could result clinically abnormal nail ; Subject peripheral vascular disease peripheral circulatory impairment ; Subject history uncontrolled diabetes mellitus ; Subject know chronic active liver disease ; Subject known immunodeficiency ; Subject family history long QT syndrome ; Subject electrocardiogram QTc interval prolongation great 450 msec male 470 msec female ; Subject potassium magnesium low low limit normal ; Subject clinically significant condition situation , condition study , opinion investigator , would interfere study evaluation optimal participation study ; Subject receive systemic antifungal therapy within 3 month topical antifungal therapy apply foot toenail within 1 month study entry ; Subject receive radiation therapy , chemotherapy , and/or immunosuppressive drug within 6 month Randomization , and/or oral corticosteroid &gt; 1 month within 6 month Randomization ( exception : inhaled steroid ) ; Subject use medication know interact azoles terfenadine , pimozide , quinidine , halofantrine , astemizole , alfentanil , cisapride , HMGCo A ( 3hydroxy3methylglutaryl coenzyme A ) reductase inhibitor metabolize CYP3A4 , ebastine , within 7 day prior Randomization ; pravastatin within 14 day prior Randomization ; Subject use medication know low serum concentration/efficacy azoles include rifampin , rifabutin , cimetidine , carbamazepine , phenytoin , barbiturate , isoniazid , 3 dos within 7 day prior Randomization ; Subject know sensitivity azoles , POS and/or excipients , terbinafine and/or excipients ; Subject previously enrol study POS investigational trial ; Subject know receive treatment investigational drug within 30 day prior enrollment study ; Woman breastfeeding , pregnant , intend become pregnant ; Subject part staff personnel directly involve study ; Subject family member investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>